# Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

Study · id `cardio:ct-nct02285985` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02285985](<https://clinicaltrials.gov/study/NCT02285985>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02285985

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02285985. Randomized; double masking; primary purpose treatment. Start 2013-02 (actual); primary completion 2019-10-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02285985, source copy `cardio:ctgov-nct02285985-2024-07-22`, retrieved 2026-10-26)
- Started: 2013-02 (actual) (ClinicalTrials.gov record NCT02285985, source copy `cardio:ctgov-nct02285985-2024-07-22`, retrieved 2026-10-26)
- Primary completion: 2019-10-12 (actual) (ClinicalTrials.gov record NCT02285985, source copy `cardio:ctgov-nct02285985-2024-07-22`, retrieved 2026-10-26)
- Completion: 2019-10-12 (actual) (ClinicalTrials.gov record NCT02285985, source copy `cardio:ctgov-nct02285985-2024-07-22`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02285985, source copy `cardio:ctgov-nct02285985-2024-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02285985-2024-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Saxagliptin on Adipose Tissue Inflammation in Humans
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Placebo
- Lead sponsor: Phoenix VA Health Care System
- Lead sponsor class: FED
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: daf727536b2ee5d81216b8b917ac27a5ad0968c8ae78c73424cc3fc0ef8b31bd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
